To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

Turning the complexity of a solid tumor against itself.

Currently active Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma.

Additional Imvax information (please click the image to read or download the PDF shown).
Imvax’s story began with a physician’s dedicated pursuit of new hope for patients with a deadly cancer, GBM. Today, the team at Imvax is driven by that same mission: to deliver transformational outcomes for people living with cancer through a new approach to personalized, whole tumor-derived immunotherapy. We are developing our proprietary immunotherapy platform, Goldspire™, to deliver a pipeline of personalized, whole tumor-derived treatments targeting intractable solid tumors.

Informed by decades of research, Imvax’s platform elegantly turns the complexity of a solid tumor against itself by capturing its complete antigenic signature and converting it into a highly immunostimulatory ‘training program’. This is designed to deliver both innate and adaptive immune stimulation to overcome the challenges of the remaining solid tumors’ cells.

Imvax’s Goldspire™ platform is a personalized, whole tumor-derived, cell-based autologous immunotherapy that delivers a full tumor antigen payload to patients by combining patient-derived tumor cells and an antisense oligodeoxynucleotide (IMV-001) against insulin-like growth factor type 1 receptor (IGF-1R). The Imvax platform is designed to be incorporated into the standard of care for GBM.
What makes Goldspire™ unique?

•  Imvax’s Goldspire™ platform exposes the full antigenic signature of a patient’s tumor to the immune system,  
   providing an opportunity for a broader anti-tumor effect compared with single antigen-targeting therapies;
•  It delivers immunotherapy that is personalized to a patient’s entire unique tumor and incorporates mechanisms that 
   stimulate both the innate and adaptive immune system;
•  The platform trains the immune system to comprehensively recognize the full antigenic signature of a patient’s 
   unique tumor. Because the immune system ignores a patient’s own antigens, Imvax’s approach should avoid 
   immune responses not directed to the tumor itself;
•  Imvax’s Goldspire™ platform uses a rapid tumor tissue processing technology; and,
•  The platform can fit within the existing standard of care for patients with resectable solid tumors.

To date, two Phase 1 clinical studies of IGV-001 in recurrent GBM and newly diagnosed GBM (ndGBM) have been completed that dosed a total of 46 patients. The larger of these trials, a Phase 1b trial of IGV-001 in 33 patients with ndGBM, was conducted and completed at Thomas Jefferson University.
Based on the encouraging results in the Phase 1 studies, Imvax initiated a Phase 2b study in 93 patients with ndGBM. The trial is being conducted at several cancer centers, generally in the Eastern half of the United States.

To learn more about the Imvax Phase 2b clinical trial in ndGBM patients, click the button below. 

“Our highest priority and motivation are the patients, families and caregivers.”
David Andrews, M.D.

Co-Founder and Chief Medical Officer
If you have further questions, 
you are welcome to contact us at: 


Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
corporate partners
upcoming events
About us
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram